**Executive takeaway:** Artivion (NYSE: AORT) is a cardiac + vascular surgery platform built around two operating segments—**Medical Devices** (aortic stent grafts, On‑X mechanical valves, surgical sealants like BioGlue, and other devices) and **Preservation Services** (implantable human tissues). ["two reportable segments"](0000784199-25-000029|0) The current growth narrative in disclosures is: **(1)** accelerating aortic stent graft growth and clinical/regulatory milestones (AMDS/Arcevo/NEXUS ecosystem), **(2)** global expansion, and **(3)** balance sheet actions (Ares credit facilities + amendments) alongside variability risks (regulatory, supply chain/single-source, and cybersecurity). ["strategic plan is focused"](0000784199-25-000029|0) ["On January 18, 2024"](0001628280-25-050502|0) ["2024 Cybersecurity Incident"](0000784199-25-000029|0) --- ## 1) “Choose your path” quick navigation (interactive) - **Business & product mix:** see **Section 2** - **Financial model & trends (FY + latest quarter):** see **Section 3** - **Balance sheet, debt, covenants & liquidity:** see **Section 4** - **Risk register (what can break the thesis):** see **Section 5** - **Governance / incentives / dilution watch:** see **Section 6** --- ## 2) What AORT actually sells (and why it matters) ### 2.1 Core product families (as described in the 10‑K) AORT frames itself as a cardiac/vascular surgery company “focused on aortic disease,” with product families spanning **aortic stent grafts**, **On‑X mechanical heart valves & related surgical products**, **surgical sealants (BioGlue)**, plus **implantable tissues** via Preservation Services. ["focused on aortic disease"](0001628280-25-050164|1) ["We have four major product families"](0000784199-24-000033|0) ### 2.2 Segment structure (how management views the business) Management discloses two reportable segments: - **Medical Devices**: aortic stent grafts, On‑X, surgical sealants, and other product revenues. ["Medical Devices segment includes"](0000784199-25-000029|0) - **Preservation Services**: preservation of cardiac and vascular tissues. ["Preservation Services segment includes"](0000784199-25-000029|0) The **CODM is the Chairman, President, and CEO**, and the **primary segment performance metric is segment gross margin** (net external revenues less cost of products/preservation services). ["Chief Operating Decision Maker"](0000784199-25-000029|0) ["primary measure of segment performance"](0000784199-25-000029|0) --- ## 3) Financial performance: “core engine” view (tables) ### 3.1 FY2024 vs FY2023: revenue by product family (USD millions) *(Scale: USD millions; converted from “in thousands” in the filing.)* | Revenue line | FY2024 | FY2023 | Y/Y | |---|---:|---:|---:| | Aortic stent grafts | 123.081 ["123,081"](0000784199-25-000029|0) | 107.469 ["107,469"](0000784199-25-000029|0) | 15% ["15%"](0000784199-25-000029|0) | | On‑X | 83.982 ["83,982"](0000784199-25-000029|0) | 74.528 ["74,528"](0000784199-25-000029|0) | 13% ["13%"](0000784199-25-000029|0) | | Surgical sealants | 73.898 ["73,898"](0000784199-25-000029|0) | 68.016 ["68,016"](0000784199-25-000029|0) | 9% ["9%"](0000784199-25-000029|0) | | Other products | 9.269 ["9,269"](0000784199-25-000029|0) | 11.172 ["11,172"](0000784199-25-000029|0) | (17)% ["(17)%"](0000784199-25-000029|0) | | **Total products** | 290.230 ["290,230"](0000784199-25-000029|0) | 261.185 ["261,185"](0000784199-25-000029|0) | 11% ["11%"](0000784199-25-000029|0) | | **Preservation services** | 98.307 ["98,307"](0000784199-25-000029|0) | 92.819 ["92,819"](0000784199-25-000029|0) | 6% ["6%"](0000784199-25-000029|0) | | **Total revenue** | **388.537** ["388,537"](0000784199-25-000029|0) | **354.004** ["354,004"](0000784199-25-000029|0) | **10%** ["10%"](0000784199-25-000029|0) | **How to read this:** The disclosures show **aortic stent grafts and On‑X** as the largest growth contributors within products in FY2024, while Preservation Services grows but is described as more variable (donor supply/yields/timing/demand). ["increase in revenues from aortic stent grafts, On-X"](0000784199-25-000029|0) ["can vary from quarter to quarter"](0000784199-25-000029|0) --- ### 3.2 Segment gross margin bridge (USD millions) | Segment | FY2024 revenue | FY2024 segment gross margin | FY2023 segment gross margin | |---|---:|---:|---:| | Medical Devices | 290.230 ["Medical devices"](0000784199-25-000029|0) | 190.845 ["Medical devices 190,845"](0000784199-25-000029|0) | 176.590 ["176,590"](0000784199-25-000029|0) | | Preservation Services | 98.307 ["Preservation services"](0000784199-25-000029|0) | 57.936 ["57,936"](0000784199-25-000029|0) | 52.586 ["52,586"](0000784199-25-000029|0) | | **Total** | 388.537 ["Total revenues 388,537"](0000784199-25-000029|0) | 248.781 ["Total gross margin 248,781"](0000784199-25-000029|0) | 229.176 ["229,176"](0000784199-25-000029|0) | --- ### 3.3 Latest “pulse check”: Q3 2025 (earnings release + 10‑Q) The Q3’25 press release (Ex‑99.1 on an 8‑K) highlights: - **Revenue $113.4m vs $95.8m (+18% GAAP)**. ["revenue of $113.4 million"](0001628280-25-050164|1) ["versus $95.8 million"](0001628280-25-050164|1) - **Adjusted EBITDA $24.6m vs $17.7m (+39%)**. ["Adjusted EBITDA increased 39%"](0001628280-25-050164|1) - Product growth callouts: **stent grafts +38%**, **On‑X +25%**, **preservation services +5%**, **BioGlue +2%** (Y/Y). ["growth in stent grafts of 38%"](0001628280-25-050164|1) And the Q3’25 Form 10‑Q provides the quarter-end balance sheet and YTD cash flow context (see Section 4). ["September 30, 2025"](0001628280-25-050502|0) --- ## 4) Balance sheet & debt: what the filings say (and what to watch) ### 4.1 Balance sheet snapshot (USD millions) | (USD mm) | Sep 30, 2025 | Dec 31, 2024 | |---|---:|---:| | Cash & equivalents | 73.426 ["Cash and cash equivalents 73,426"](0001628280-25-050502|0) | 53.463 ["53,463"](0001628280-25-050502|0) | | Total assets | 857.662 ["Total assets 857,662"](0001628280-25-050502|0) | 789.101 ["789,101"](0001628280-25-050502|0) | | Total debt (net) | 214.869 ["Long-term debt, net 214,869"](0001628280-25-050502|0) | 314.152 ["314,152"](0001628280-25-050502|0) | | Total liabilities | 418.968 ["Total liabilities 418,968"](0001628280-25-050502|0) | 512.901 ["512,901"](0001628280-25-050502|0) | | Stockholders’ equity | 438.694 ["Total stockholders’ equity 438,694"](0001628280-25-050502|0) | 276.200 ["276,200"](0001628280-25-050502|0) | A notable structural driver here is the **settlement of the Convertible Senior Notes** in 2025 (including issuance of shares and a small cash interest payment), which reduces principal debt vs year-end 2024. ["Holders exchanged"](0001628280-25-050502|0) ["Convertible Senior Notes —"](0001628280-25-050502|0) ### 4.2 Credit facilities: terms + covenants (high-signal excerpt) From the Q3’25 10‑Q, AORT discloses: - Ares credit agreement (initially **$350m total facilities**) including **$190m term loan**, **$100m delayed draw** (later terminated), and **$60m revolver** (with $30m drawn at closing). ["$350.0 million"](0001628280-25-050502|0) ["borrowed $190.0 million"](0001628280-25-050502|0) ["$30.0 million"](0001628280-25-050502|0) - A **Second Amendment** extending maturity to **Jan 18, 2031**, reducing margins, and creating a **new $150m delayed draw facility** available through **Sep 12, 2027** (subject to leverage test and conditions). ["extension ... to January 18, 2031"](0001628280-25-050502|0) ["new $150.0 million"](0001628280-25-050502|0) ["on or prior to September 12, 2027"](0001628280-25-050502|0) - A maintenance covenant: total net leverage ratio **≤ 5.75x from Q1 2025 onward**; company states it was **in compliance** as of Sep 30, 2025. ["not greater than 5.75x"](0001628280-25-050502|0) ["we are in compliance"](0001628280-25-050502|0) **Why this matters:** the filings are telling you the company’s “optionality” for acquisitions/earnouts/capex is tightly linked to (i) delayed draw availability and (ii) leverage covenant headroom. ["fund permitted acquisitions"](0001628280-25-050502|0) ["maximum total net leverage ratio"](0001628280-25-050502|0) --- ## 5) Risk register (filing-grounded): what can break the story Below are **high-signal risk clusters** explicitly surfaced across the 10‑K/10‑Q disclosures. ### 5.1 Regulatory + clinical execution risk AORT discloses extensive regulatory regimes (FDA, CE Mark/MDR, etc.) and highlights product-specific regulatory sensitivities (e.g., tissue classification risk for CryoValve SGPV). ["highly regulated"](0000784199-25-000029|0) ["reclassification"](0000784199-25-000029|0) ### 5.2 Single/sole-source & manufacturing concentration The 10‑K is explicit that certain products/services/components are **single- or sole-sourced**, raising disruption risk and bargaining power risk. ["single- or sole-source suppliers"](0000784199-25-000029|0) ### 5.3 Cybersecurity incident overhang (costs + uncertainty) The 10‑K states the 2024 cybersecurity incident had a quantified impact on FY2024 results and references expected ongoing professional fees in 2025 (per 10‑Q). ["$4.6 million impact"](0000784199-25-000029|0) ["continue to incur professional fees"](0001628280-25-050502|0) ### 5.4 Leverage / covenant / refinancing risk The 10‑Q risk-factor section includes detailed language on restrictions imposed by debt agreements and the consequences of default. ["restrictions that limit"](0001628280-25-050502|0) ["event of default"](0001628280-25-050502|0) --- ## 6) Governance & incentives (dilution + alignment watch) ### 6.1 Equity plan replenishment (potential dilution focus) The 2025 proxy asks stockholders to approve **additional funding of 3,570,000 shares** for the 2020 Equity and Cash Incentive Plan (ECIP). ["additional funding of 3,570,000 shares"](0001999371-25-003629|0) It also provides “overhang” framing: outstanding awards + available shares under ECIP total 4,104,636 (9.6% of outstanding shares), rising materially if the new shares are approved. ["overhang” total 4,104,636"](0001999371-25-003629|0) ["increase our overhang"](0001999371-25-003629|0) ### 6.2 Pay-for-performance mechanics (what they say they pay on) The proxy discloses incentive plan metrics including **constant currency revenue growth** and **adjusted EBITDA**, and discusses adjustments tied to the cybersecurity incident impacts. ["constant currency revenue growth"](0001999371-25-003629|0) ["adjusted EBITDA"](0001999371-25-003629|0) ["Cybersecurity Incident"](0001999371-25-003629|0) --- ## “Interactive drill-down” appendix (open/close) <details> <summary><b>A) Key filings used (click to expand)</b></summary> - FY2024 Form 10‑K (filed Feb 28, 2025): (0000784199-25-000029|0) - Q3 2025 Form 10‑Q (filed Nov 7, 2025): (0001628280-25-050502|0) - Q3 2025 earnings release (Ex‑99.1 to 8‑K filed Nov 6, 2025): (0001628280-25-050164|1) - 2025 Proxy Statement (DEF 14A filed Apr 1, 2025): (0001999371-25-003629|0) </details> <details> <summary><b>B) “Fast thesis checklist” you can reuse (click to expand)</b></summary> 1) Is **aortic stent graft growth** sustaining and translating to margin? ["stent grafts of 38%"](0001628280-25-050164|1) 2) Are **clinical/reg milestones** staying on timeline (AMDS/Arcevo/NEXUS ecosystem)? ["AMDS"](0000784199-25-000029|0) ["ARTIZEN trial"](0001628280-25-050164|1) 3) Is **preservation services volatility** manageable (donor supply/yields/pricing)? ["can vary from quarter-to-quarter"](0000784199-25-000029|0) 4) Is **leverage covenant headroom** preserved while using delayed draw for M&A/earnouts? ["not greater than 5.75x"](0001628280-25-050502|0) ["New Delayed Draw"](0001628280-25-050502|0) 5) Does **equity plan replenishment** meaningfully change dilution trajectory? ["3,570,000 shares"](0001999371-25-003629|0) </details> --- If you want, I can continue the deep dive by building a **multi-period model table** (FY2022–FY2024 + YTD 2025) focused on (i) gross margin structure, (ii) opex intensity (G&A + R&D), and (iii) interest burden and debt evolution—strictly from the 10‑K/10‑Q/8‑K tables already cited above.

**Executive takeaway:** Artivion (NYSE: AORT) is a cardiac + vascular surgery platform built around two operating segments—**Medical Devices** (aortic stent grafts, On‑X mechanical valves, surgical sealants like BioGlue, and other devices) and **Preservation Services** (implantable human tissues). ["two reportable segments"](0000784199-25-000029|0) The current growth narrative in disclosures is: **(1)** accelerating aortic stent graft growth and clinical/regulatory milestones (AMDS/Arcevo/NEXUS ecosystem), **(2)** global expansion, and **(3)** balance sheet actions (Ares credit facilities + amendments) alongside variability risks (regulatory, supply chain/single-source, and cybersecurity). ["strategic plan is focused"](0000784199-25-000029|0) ["On January 18, 2024"](0001628280-25-050502|0) ["2024 Cybersecurity Incident"](0000784199-25-000029|0) --- ## 1) “Choose your path” quick navigation (interactive) - **Business & product mix:** see **Section 2** - **Financial model & trends (FY + latest quarter):** see **Section 3** - **Balance sheet, debt, covenants & liquidity:** see **Section 4** - **Risk register (what can break the thesis):** see **Section 5** - **Governance / incentives / dilution watch:** see **Section 6** --- ## 2) What AORT actually sells (and why it matters) ### 2.1 Core product families (as described in the 10‑K) AORT frames itself as a cardiac/vascular surgery company “focused on aortic disease,” with product families spanning **aortic stent grafts**, **On‑X mechanical heart valves & related surgical products**, **surgical sealants (BioGlue)**, plus **implantable tissues** via Preservation Services. ["focused on aortic disease"](0001628280-25-050164|1) ["We have four major product families"](0000784199-24-000033|0) ### 2.2 Segment structure (how management views the business) Management discloses two reportable segments: - **Medical Devices**: aortic stent grafts, On‑X, surgical sealants, and other product revenues. ["Medical Devices segment includes"](0000784199-25-000029|0) - **Preservation Services**: preservation of cardiac and vascular tissues. ["Preservation Services segment includes"](0000784199-25-000029|0) The **CODM is the Chairman, President, and CEO**, and the **primary segment performance metric is segment gross margin** (net external revenues less cost of products/preservation services). ["Chief Operating Decision Maker"](0000784199-25-000029|0) ["primary measure of segment performance"](0000784199-25-000029|0) --- ## 3) Financial performance: “core engine” view (tables) ### 3.1 FY2024 vs FY2023: revenue by product family (USD millions) *(Scale: USD millions; converted from “in thousands” in the filing.)* | Revenue line | FY2024 | FY2023 | Y/Y | |---|---:|---:|---:| | Aortic stent grafts | 123.081 ["123,081"](0000784199-25-000029|0) | 107.469 ["107,469"](0000784199-25-000029|0) | 15% ["15%"](0000784199-25-000029|0) | | On‑X | 83.982 ["83,982"](0000784199-25-000029|0) | 74.528 ["74,528"](0000784199-25-000029|0) | 13% ["13%"](0000784199-25-000029|0) | | Surgical sealants | 73.898 ["73,898"](0000784199-25-000029|0) | 68.016 ["68,016"](0000784199-25-000029|0) | 9% ["9%"](0000784199-25-000029|0) | | Other products | 9.269 ["9,269"](0000784199-25-000029|0) | 11.172 ["11,172"](0000784199-25-000029|0) | (17)% ["(17)%"](0000784199-25-000029|0) | | **Total products** | 290.230 ["290,230"](0000784199-25-000029|0) | 261.185 ["261,185"](0000784199-25-000029|0) | 11% ["11%"](0000784199-25-000029|0) | | **Preservation services** | 98.307 ["98,307"](0000784199-25-000029|0) | 92.819 ["92,819"](0000784199-25-000029|0) | 6% ["6%"](0000784199-25-000029|0) | | **Total revenue** | **388.537** ["388,537"](0000784199-25-000029|0) | **354.004** ["354,004"](0000784199-25-000029|0) | **10%** ["10%"](0000784199-25-000029|0) | **How to read this:** The disclosures show **aortic stent grafts and On‑X** as the largest growth contributors within products in FY2024, while Preservation Services grows but is described as more variable (donor supply/yields/timing/demand). ["increase in revenues from aortic stent grafts, On-X"](0000784199-25-000029|0) ["can vary from quarter to quarter"](0000784199-25-000029|0) --- ### 3.2 Segment gross margin bridge (USD millions) | Segment | FY2024 revenue | FY2024 segment gross margin | FY2023 segment gross margin | |---|---:|---:|---:| | Medical Devices | 290.230 ["Medical devices"](0000784199-25-000029|0) | 190.845 ["Medical devices 190,845"](0000784199-25-000029|0) | 176.590 ["176,590"](0000784199-25-000029|0) | | Preservation Services | 98.307 ["Preservation services"](0000784199-25-000029|0) | 57.936 ["57,936"](0000784199-25-000029|0) | 52.586 ["52,586"](0000784199-25-000029|0) | | **Total** | 388.537 ["Total revenues 388,537"](0000784199-25-000029|0) | 248.781 ["Total gross margin 248,781"](0000784199-25-000029|0) | 229.176 ["229,176"](0000784199-25-000029|0) | --- ### 3.3 Latest “pulse check”: Q3 2025 (earnings release + 10‑Q) The Q3’25 press release (Ex‑99.1 on an 8‑K) highlights: - **Revenue $113.4m vs $95.8m (+18% GAAP)**. ["revenue of $113.4 million"](0001628280-25-050164|1) ["versus $95.8 million"](0001628280-25-050164|1) - **Adjusted EBITDA $24.6m vs $17.7m (+39%)**. ["Adjusted EBITDA increased 39%"](0001628280-25-050164|1) - Product growth callouts: **stent grafts +38%**, **On‑X +25%**, **preservation services +5%**, **BioGlue +2%** (Y/Y). ["growth in stent grafts of 38%"](0001628280-25-050164|1) And the Q3’25 Form 10‑Q provides the quarter-end balance sheet and YTD cash flow context (see Section 4). ["September 30, 2025"](0001628280-25-050502|0) --- ## 4) Balance sheet & debt: what the filings say (and what to watch) ### 4.1 Balance sheet snapshot (USD millions) | (USD mm) | Sep 30, 2025 | Dec 31, 2024 | |---|---:|---:| | Cash & equivalents | 73.426 ["Cash and cash equivalents 73,426"](0001628280-25-050502|0) | 53.463 ["53,463"](0001628280-25-050502|0) | | Total assets | 857.662 ["Total assets 857,662"](0001628280-25-050502|0) | 789.101 ["789,101"](0001628280-25-050502|0) | | Total debt (net) | 214.869 ["Long-term debt, net 214,869"](0001628280-25-050502|0) | 314.152 ["314,152"](0001628280-25-050502|0) | | Total liabilities | 418.968 ["Total liabilities 418,968"](0001628280-25-050502|0) | 512.901 ["512,901"](0001628280-25-050502|0) | | Stockholders’ equity | 438.694 ["Total stockholders’ equity 438,694"](0001628280-25-050502|0) | 276.200 ["276,200"](0001628280-25-050502|0) | A notable structural driver here is the **settlement of the Convertible Senior Notes** in 2025 (including issuance of shares and a small cash interest payment), which reduces principal debt vs year-end 2024. ["Holders exchanged"](0001628280-25-050502|0) ["Convertible Senior Notes —"](0001628280-25-050502|0) ### 4.2 Credit facilities: terms + covenants (high-signal excerpt) From the Q3’25 10‑Q, AORT discloses: - Ares credit agreement (initially **$350m total facilities**) including **$190m term loan**, **$100m delayed draw** (later terminated), and **$60m revolver** (with $30m drawn at closing). ["$350.0 million"](0001628280-25-050502|0) ["borrowed $190.0 million"](0001628280-25-050502|0) ["$30.0 million"](0001628280-25-050502|0) - A **Second Amendment** extending maturity to **Jan 18, 2031**, reducing margins, and creating a **new $150m delayed draw facility** available through **Sep 12, 2027** (subject to leverage test and conditions). ["extension ... to January 18, 2031"](0001628280-25-050502|0) ["new $150.0 million"](0001628280-25-050502|0) ["on or prior to September 12, 2027"](0001628280-25-050502|0) - A maintenance covenant: total net leverage ratio **≤ 5.75x from Q1 2025 onward**; company states it was **in compliance** as of Sep 30, 2025. ["not greater than 5.75x"](0001628280-25-050502|0) ["we are in compliance"](0001628280-25-050502|0) **Why this matters:** the filings are telling you the company’s “optionality” for acquisitions/earnouts/capex is tightly linked to (i) delayed draw availability and (ii) leverage covenant headroom. ["fund permitted acquisitions"](0001628280-25-050502|0) ["maximum total net leverage ratio"](0001628280-25-050502|0) --- ## 5) Risk register (filing-grounded): what can break the story Below are **high-signal risk clusters** explicitly surfaced across the 10‑K/10‑Q disclosures. ### 5.1 Regulatory + clinical execution risk AORT discloses extensive regulatory regimes (FDA, CE Mark/MDR, etc.) and highlights product-specific regulatory sensitivities (e.g., tissue classification risk for CryoValve SGPV). ["highly regulated"](0000784199-25-000029|0) ["reclassification"](0000784199-25-000029|0) ### 5.2 Single/sole-source & manufacturing concentration The 10‑K is explicit that certain products/services/components are **single- or sole-sourced**, raising disruption risk and bargaining power risk. ["single- or sole-source suppliers"](0000784199-25-000029|0) ### 5.3 Cybersecurity incident overhang (costs + uncertainty) The 10‑K states the 2024 cybersecurity incident had a quantified impact on FY2024 results and references expected ongoing professional fees in 2025 (per 10‑Q). ["$4.6 million impact"](0000784199-25-000029|0) ["continue to incur professional fees"](0001628280-25-050502|0) ### 5.4 Leverage / covenant / refinancing risk The 10‑Q risk-factor section includes detailed language on restrictions imposed by debt agreements and the consequences of default. ["restrictions that limit"](0001628280-25-050502|0) ["event of default"](0001628280-25-050502|0) --- ## 6) Governance & incentives (dilution + alignment watch) ### 6.1 Equity plan replenishment (potential dilution focus) The 2025 proxy asks stockholders to approve **additional funding of 3,570,000 shares** for the 2020 Equity and Cash Incentive Plan (ECIP). ["additional funding of 3,570,000 shares"](0001999371-25-003629|0) It also provides “overhang” framing: outstanding awards + available shares under ECIP total 4,104,636 (9.6% of outstanding shares), rising materially if the new shares are approved. ["overhang” total 4,104,636"](0001999371-25-003629|0) ["increase our overhang"](0001999371-25-003629|0) ### 6.2 Pay-for-performance mechanics (what they say they pay on) The proxy discloses incentive plan metrics including **constant currency revenue growth** and **adjusted EBITDA**, and discusses adjustments tied to the cybersecurity incident impacts. ["constant currency revenue growth"](0001999371-25-003629|0) ["adjusted EBITDA"](0001999371-25-003629|0) ["Cybersecurity Incident"](0001999371-25-003629|0) --- ## “Interactive drill-down” appendix (open/close) <details> <summary><b>A) Key filings used (click to expand)</b></summary> - FY2024 Form 10‑K (filed Feb 28, 2025): (0000784199-25-000029|0) - Q3 2025 Form 10‑Q (filed Nov 7, 2025): (0001628280-25-050502|0) - Q3 2025 earnings release (Ex‑99.1 to 8‑K filed Nov 6, 2025): (0001628280-25-050164|1) - 2025 Proxy Statement (DEF 14A filed Apr 1, 2025): (0001999371-25-003629|0) </details> <details> <summary><b>B) “Fast thesis checklist” you can reuse (click to expand)</b></summary> 1) Is **aortic stent graft growth** sustaining and translating to margin? ["stent grafts of 38%"](0001628280-25-050164|1) 2) Are **clinical/reg milestones** staying on timeline (AMDS/Arcevo/NEXUS ecosystem)? ["AMDS"](0000784199-25-000029|0) ["ARTIZEN trial"](0001628280-25-050164|1) 3) Is **preservation services volatility** manageable (donor supply/yields/pricing)? ["can vary from quarter-to-quarter"](0000784199-25-000029|0) 4) Is **leverage covenant headroom** preserved while using delayed draw for M&A/earnouts? ["not greater than 5.75x"](0001628280-25-050502|0) ["New Delayed Draw"](0001628280-25-050502|0) 5) Does **equity plan replenishment** meaningfully change dilution trajectory? ["3,570,000 shares"](0001999371-25-003629|0) </details> --- If you want, I can continue the deep dive by building a **multi-period model table** (FY2022–FY2024 + YTD 2025) focused on (i) gross margin structure, (ii) opex intensity (G&A + R&D), and (iii) interest burden and debt evolution—strictly from the 10‑K/10‑Q/8‑K tables already cited above.